Kornimate/medical-research-clean huggingface dataset:
the effect of preemptive levator ani injections on pain after pelvic reconstructive surgery

Conditions: Pelvic Floor Prolapse; Surgery; Pain, Postoperative

Summary: patients undergoing vaginal pelvic reconstructive surgery for pelvic organ prolapse (pop) under general anesthesia will be randomized to receive bilateral trans-vaginal pelvic floor muscle injections with bupivacaine or no injection (standard of care) as a part of their surgical pain control

patients undergoing vaginal pelvic reconstructive surgery for pelvic organ prolapse (pop) under general anesthesia will be randomized to receive: 1. bilateral trans- vaginal pelvic floor levator ani muscle injections (trigger point injections) with bupivacaine: - 0.5% bupivacaine will be injected at several sites for a total of 5ml on each side of the pelvic floor, with each injection site no more than 1 ml (bupivacaine was chosen by the study team because of it has a longer half life then other common local anesthetics. we plan to use the same anesthetic and dosage to standardize the protocol between patients. other local anesthetics will not be used in addition to the bupivacaine administered for research purposes. we will limit the amount of intravenous lidocaine to less than 5mg/ kg). 2. control- no additional treatment (standard of care). the patient will be blinded to their randomization (single blind). the post-operative pain regimen will be standardized when possible. patients will receive a regimen of iv and oral narcotics and ketorolac per our routine post-operative protocol. on discharge from the hospital, patients will be given prescriptions for a standard amount of oral narcotic, 20 tablets of oxycodone (150 morphine equivalents), and 30 tablets of 600mg ibuprofen.

Eligibility criteria:
inclusion criteria: * female * able to read english and give informed consent * undergoing vaginal pelvic reconstructive surgery for pop exclusion criteria: * hypersensitivity or allergy to amide anesthetics * documented chronic pain condition o (back pain, pelvic pain, fibromyalgia, etc.) * bleeding disorder * connective tissue disorder * neuromuscular disorder * cardiac conduction abnormality or channelopathy * hepatic impairment * renal impairment * history of, or current, narcotic or alcohol dependence * history of pelvic radiation or gynecologic malignancy
assess itch behavior in nickel sulphate sensitized volunteers

Conditions: Allergic Contact Eczema

Summary: determine the mean time to itch relief from the start of treatment with topic methylprednisolone aceponate.


Eligibility criteria:
inclusion criteria: 1. subjects ≥18 years old. 2. subjects with a history of diagnosis of sensitization to nickel sulphate. 3. delayed type hypersensitivity demonstrated by positive reaction with epicutaneous or patch test. 4. skin phototype ii-iii. 5. women with fertile age and a negative result in the pregnancy test before inclusion. women must use an adequate contraceptive method during the study. 6. written informed consent prior to inclusion. 7. able and willing to comply with protocol procedures and to follow the investigator's instructions. criteria for treatment initiation: at day 7, before starting treatment, subjects must meet the inclusion criteria and all the following criteria: ≥ 3 vas and eczema intensity of (+ +) or (+++) according to icdrg scale. exclusion criteria: 1. active cutaneous disease causing itch (active eczema, urticaria or insect bites) 2. active systemic disease that may induce itch (hepatic or renal disease). 3. active psychiatric disease that could interfere with symptom assessment. 4. treatment with drugs inducing itch. 5. treatment with oral or topical preparations that could interfere with the itching sensation induced by patch test. 6. treatment with systemic or topical corticosteroids, antihistaminics or calcineurin inhibitors. 7. active skin disease in the back that may interfere with the assessment of response to topical application of allergen 8. pregnancy or lactation 9. subjects with contraindications specified in summary of product characteristics (spc).
the türkiye heart failure registry

Conditions: Heart Failure

Summary: a comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. the identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. a comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. it should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. therefore, the türkiye heart failure (turk-hf) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.


Eligibility criteria:
inclusion criteria: presence of heart failure - exclusion criteria: age \<18 years -
fostering mat use in justice populations

Conditions: Opioid-use Disorder; Recidivism

Summary: the grant will test two timely and successful evidence-based implementation practices, niatx coaching and echo, with jail/community-based healthcare providers to increase medication assisted treatment (mat) use with justice populations.

in this trial, the investigators will test two implementation interventions being applied to medications for opioid use disorder (moud) dissemination and implementation in justice settings for justice-involved populations: niatx coaching and the extension for community healthcare outcomes (echo) model. niatx coaches provide expertise in moud implementation and organizational change to help treatment organizations and staff make, sustain, and spread moud. the echo platform focuses only on the provider side by connecting the primary care provider with expert moud prescribers to promote high-quality moud practices. this will be the first trial that assesses the comparative effectiveness of these approaches overall, and in justice settings. the trial will be conducted with a combination of 48 jails and community-based organizations that treat individuals with opioid use disorders (ouds) post-incarceration. sites will be randomly assigned to one of four study arms, with 12 sites in each arm: high-dose coaching/echo, low-dose coaching/echo, high-dose coaching/no echo, and low-dose coaching/no echo. the intervention period will be over a 12-month span with an additional 12-months for sustainability.

Eligibility criteria:
site inclusion criteria: * have an interest in embedding or increasing the use of moud within their site. * have the funds to pay for medications for the duration of the study (24 months); whether it be from grants, insurance or private pay. * sites agree to implement or continue to use at least one medication, although they will be encouraged to offer more than one medication. * have leadership support at all levels. * agree to provide data described in the mou or information sheet. exclusion criteria: * n/a

Keywords: moud oud justice populations jails echo niatx inter-agency
pericoronary inflammation in non-obstructive coronary artery disease

Conditions: Non-Obstructive Coronary Atherosclerosis

Summary: among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (cad). myocardial infarction (mi) with non-obstructive coronary artery disease (minoca) accounts for 5-20% of patients with mi and preferentially affects women. minoca pathogenesis is varied and may include atherosclerotic plaque rupture, plaque erosion with thrombosis, vasospasm, embolization, dissection or a combination of mechanisms. other patients may have clinically unrecognized myocarditis, or takotsubo syndrome masquerading as mi. among patients referred for coronary angiography for the evaluation of stable ischemic heart disease, non-obstructive cad is present in up to \~30% of men and \~60% of women. stable ischemia with non-obstructive coronary arteries (inoca) may be due to coronary microvascular dysfunction in up to 40% of these patients. our understanding of mechanisms of minoca and inoca remain incomplete. coronary inflammation has been hypothesized as a potential mechanism contributing to coronary spasm in minoca and microvascular disease in inoca.

the pericoronary inflammation in non-obstructive coronary artery disease (point-nocad) study is a single-center diagnostic, observational study enrolling men and women with minoca or inoca who are planned to undergo (or underwent) clinically indicated coronary angiography. the research plan is to evaluate coronary inflammation, as measured by the perivascular coronary fat attenuation index from non-invasive coronary computed tomography angiography (ccta), in patients with minoca and inoca.

Eligibility criteria:
inclusion criteria: * adult age ≥18 years referred for clinically indicated coronary angiography * stable ischemic heart disease or acute myocardial infarction as the indication for coronary angiography exclusion criteria: clinical exclusion criteria: * estimated glomerular filtration rate \< 45 ml/min * history of allergic reaction to iodinated contrast media * pregnancy angiographic / post-cath exclusion criteria: * obstructive cad (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography) * allergic reaction to iodinated contrast media
effects of schroth method and proprioceptive neuromuscular facilitation technique in patients with idiopathic scoliosis

Conditions: Idiopathic Scoliosis

Summary: the aim of this study is to compare the effects of schroth method and proprioceptive neuromuscular facilitation techniques on pain, mobility, and quality of life in patients with idiopathic scoliosis.

scoliosis is a three-dimensional deformity that causes the spine to curve sideways. the most common type of scoliosis is "idiopathic," which means the exact cause is unknown. it accounts for approximately 85% of cases. the prevalence rate of 2-5% with a cobb angle greater than 10 degrees. all previous studies in which schroth method with other different techniques has been performed have shown greater improvement in the management of scoliosis. however, there is no clinical significance work on the comparative effect of the schroth method and pnf. previous literature showed no significant improvement in mobility and quality of life. this study aims to find evidence of clinical significance work on effects of schroth method and proprioceptive neuromuscular facilitation technique on pain, mobility, and quality of life in patients with idiopathic scoliosis in both gender

Eligibility criteria:
inclusion criteria: * participants with lenke curve type 1 scoliosis and other types of scoliotic curve magnitude will be included. * cobb angle 10-30 exclusion criteria: * participants with any surgical and traumatic history of spine * participants prescribed with brace treatment * subjects with non-idiopathic scoliosis * subjects with any systematic disease e.g. (cardiovascular, vestibular, rheumatological, neuromuscular and pulmonary disease)

Keywords: idiopathic scoliosis schroth method proprioceptive neuromuscular facilitation techniques
improvement of range of motion in frozen shoulder in breast cancer survivors

Conditions: Breast Neoplasm; Shoulder Capsulitis; Range of Motion

Summary: the prevalence of shoulder joint disease is high in breast cancer patients. the cause of adhesive capsulitis is not clearly identified. however, the following are known as relevant factors that are the restriction of the use of the arm after surgery, inflammation due to autoimmune action, radiation therapy, and adhesion of the surgical site. the purpose of this study is to compare and analyze the effect of intrathecal steroid injection in breast cancer survivors with adhesive capsulitis.


Eligibility criteria:
inclusion criteria: * patients who underwent breast cancer surgery within 6 months. * patients with shoulder pain and limited range of motion exclusion criteria: * patients with infection * bilateral shoulder pain patient * patients with uncontrolled diabetes
predictors and outcomes of kangaroo mother care: a quasi-experimental study in pakistan

Conditions: Low Birth Weight Infants; Preterm Infants

Summary: this quasi-experimental study evaluated the impact of kangaroo mother care (kmc) versus conventional care (cc) on the growth, developmental milestones, breastfeeding, vaccination, and mortality of low birth weight infants in services hospital lahore, pakistan. a total of 400 infants were enrolled and followed for one year.

this quasi-experimental study was conducted in the obstetrics and gynecology department of services institute of medical sciences (sims), lahore, pakistan, to compare the impact of kangaroo mother care (kmc) versus conventional care (cc) on low birth weight infants. a total of 400 infants (200 in each group) born between january 2020 and december 2022 were included in the study, with participants selected based on specific inclusion criteria and informed consent obtained. kmc involved continuous skin-to-skin contact between mother and infant during the hospital stay and continued at home for at least 8 hours daily. the follow-up schedule included appointments at six weeks after birth, monthly visits until six months of age, and quarterly visits until the infants reached one year of age. during these visits, the study collected data on infant growth, developmental milestones, breastfeeding practices, and vaccination status. the study was ethically approved by the research ethics committee, and data collection was conducted during scheduled follow-up visits to the outpatient department.

Eligibility criteria:
inclusion criteria: * women who were able to follow the program instructions, * permanent residents of lahore and its periphery and willing to be part of program for the one-year time period, * live newborn babies delivered either vaginally or through caesarean section with birth weight of 1.5 to 2 kg, * gestational age between 28 to 36 weeks. exclusion criteria: * an infant or mother diagnosed with a life-threatening ailment, major disease, or major malformations, * early-detected major conditions arising from perinatal problems, such as severe hypoxic-ischemic encephalopathy, pulmonary hypertension, * incidence of severe infection measured as nosocomial infections requiring systemic antibiotics or infections, severe respiratory distress, and hypothermia episodes (temperature less than 35c).

Keywords: kangroo mother care infant development breast feeding neonatal death vaccination pakistan
emergency department telephone quitline

Conditions: Tobacco Dependence

Summary: the purpose of this preliminary study was to evaluate the intervention completion rate among cigarette smokers enrolled through the emergency department (ed) in a tobacco quitline (ql) and to assess the feasibility of a randomized controlled trial assessing the efficacy of this intervention.

this pilot study was a prospective, randomized, controlled, un-blinded study using a convenience sample of cigarettes smokers recruited through the ed. utilizing a computerized block randomization schedule, subjects were randomized in blocks of four to receive a proactive ql intervention through an established ql or a united states public health service (usphs) self-help manual. proactive telephone counseling describes counseling that is initiated by a counselor rather than the subject. both groups received strong advice to quit from study personnel. names and telephone numbers of patients randomized to the ql group were faxed to the ql which then initiated contact with the patient. multiple contact attempts were made over the following week by telephone. patients in the ql were instructed to call the ql if they had not been reached in one week. ql counseling involved an initial 45-minute telephone session followed by up to four 10 to 15 minute follow-up sessions around their identified quit date. ql patients not successfully contacted within one week of enrollment were sent a letter inviting them to call as well as information on strategies to help them quit.

Eligibility criteria:
inclusion criteria: * we enrolled patients aged 18 or older who reported current daily cigarette smoking for at least one year and who indicated an interest in attempting to quit smoking.
a randomized controlled trial for patients underwent total hip arthroplasties assisted by surgical navigation system

Conditions: Hip Arthropathy

Summary: this is a randomized controlled, multicenter study. according to the inclusion criteria, volunteers were recruited from patients undergoing total hip arthroplasty. after signing the informed consent, the subjects were assigned to the experimental group and the control group through the central randomization system. the researchers will complete the total hip arthroplasty for patients in the experimental group with the assistance of surgical navigation system. the patients in the control group do not use the surgical navigation system. the proportion of acetabular abduction angle and anteversion angle in the lewinnek safe area is the primary outcome measurement. the operation time, womac score, harris score, range of motion and dislocation rate are the secondaryoutcome measurements. the incidence of complications, devices and other adverse events were recorded.


Eligibility criteria:
inclusion criteria: clinical diagnosis of primary hip osteoarthritis(oa), fracture of femoral neck (ffn),or secondary hip osteoarthritis due to developmental dysplasia of the hip (ddh), hip avascular necrosis (avn), rheumatoid arthritis (ra), ankylosing spondylitis (as), and coxa plana exclusion criteria: severe vascular diseases of the lower extremity neuromuscular diseases infectious diseases severe dysfunctions of major organs severe neurosensory deficiencies caused by spinal diseases unable to receive ct/mri scans
role of immune system in obesity-related inflammation and cardiometabolic risk

Conditions: Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Metabolically Abnormal Obesity; Metabolically Normal Obesity; Obesity

Summary: the purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others. understanding this may lead to better treatments for diseases such as diabetes and cardiovascular disease.

the purpose of this study is to determine the specific cellular and organ system metabolic and immunologic alterations that are associated with insulin resistance and inflammation in order to identify putative mechanisms and novel bio-markers involved in the pathogenesis and progression of inflammatory and cardiometabolic diseases.

Eligibility criteria:
inclusion criteria: lean, metabolically healthy group - body mass index (bmi) 18.5-24.9 kg/m2, hba1c ≤5.6%, fasting plasma glucose concentration \<100 mg/dl, 2-h ogtt plasma glucose concentration \<140 mg/dl and intrahepatic triglyceride (ihtg) content ≤5%. obese, metabolically healthy group - bmi ≥30 kg/m2, hhba1c ≤5.6%, fasting plasma glucose concentration \<100 mg/dl, 2-h ogtt plasma glucose concentration \<140 mg/dl and intrahepatic triglyceride (ihtg) content ≤5%. obese, metabolically healthy group - bmi ≥30 kg/m2, ihtg content ≥5.6% and hba1c ≥5.7% or fasting plasma glucose concentration ≥100 mg/dl or 2-h ogtt plasma glucose concentration ≥140 mg/dl. lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery - bmi 18.5-24.9 kg/m2, hba1c ≤5.6%, fasting plasma glucose concentration \<100 mg/dl, 2-h ogtt plasma glucose concentration \<140 mg/dl and ihtg content ≤5%. obese, scheduled for bariatric and gallbladder surgery - bmi ≥35.0kg/m2 exclusion criteria: * active or previous history of liver diseases other than nafld * history of alcohol abuse * currently consuming ≥20 g alcohol/day * severe hypertriglyceridemia (\>300 mg/dl) * smoke tobacco * cancer diagnosis within the previous 5 years * medications that might confound the study results * pregnancy or lactation * exercise \>2 h/week

Keywords: nafld obesity metabolic syndrome
dose-response study of arginine supplementation in severe sepsis

Conditions: Sepsis; Septic Shock

Summary: pilot data in patients and data from pig studies indicate that arginine-no metabolism is impaired in sepsis with changes in splanchnic metabolism and function, and reduced survival at low nitrate levels. prolonged intravenous supplementation of l-arginine proved effective in pigs for increasing no production, restoring gut function, and inhibiting an increase in pulmonary arterial pressure, without any deleterious systemic side effects. prolonged intravenous l-arginine supplementation could therefore be useful in septic icu patients.


Eligibility criteria:
inclusion criteria: * written informed consent from close relative * age \> 18 years * patient meets the general criteria for severe sepsis or septic shock, diagnosed less than 48 h prior to study inclusion (see appendix a; in dutch). * patient must be relatively hemodynamically stable, defined as stable blood pressure (variation in mean arterial pressure \<15 mm hg) during 2 h without necessity of increasing the vasopressor dose, inotropic support or rate of fluid administration. * systemic and pulmonary arterial catheters in place with continuous pressure monitoring. * patients in whom the clinician is prepared to provide full life support during the duration of the study, including a life expectance of \> 24 h. exclusion criteria: * shock due to any cause other than sepsis (e.g. drug reaction or drug overdose, pulmonary embolus, burn injury etc.) * corticosteroid use (prolonged intake of \> 1mg/kg daily or intake of \> 70 mg/day for 7 consecutive days within 1 month preceding the study) * liver cirrhosis * chronic pancreatitis * diabetes mellitus type i * metastases, haematological malignancies or chemotherapy * patients on dialysis (cvvh or other)